Financial reports
10-Q
2023 Q3
Quarterly report
6 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
5 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
10-Q
2022 Q1
Quarterly report
4 May 22
10-K
2021 FY
Annual report
28 Feb 22
10-Q
2021 Q3
Quarterly report
8 Nov 21
Current reports
8-K
Contingent Value Rights Agreement
23 Jan 24
8-K
Other Events
19 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
13 Dec 23
8-K
Other Events
24 Nov 23
8-K
Other Events
13 Nov 23
8-K
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
6 Nov 23
8-K
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics
10 Oct 23
8-K
Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer
23 Aug 23
8-K
Mirati Therapeutics Announces Proposed Public Offering
9 Aug 23
8-K
Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
8 Aug 23
Registration and prospectus
15-12G
Securities registration termination
2 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Jan 24
Proxies
DEFA14A
Additional proxy soliciting materials
6 Dec 23
DEFA14A
Additional proxy soliciting materials
1 Dec 23
DEFA14A
Additional proxy soliciting materials
15 Nov 23
DEFM14A
Proxy related to merger
2 Nov 23
PREM14A
Preliminary proxy related to merger
23 Oct 23
DEFA14A
Additional proxy soliciting materials
12 Oct 23
DEFA14A
Additional proxy soliciting materials
11 Oct 23
DEFA14A
Additional proxy soliciting materials
10 Oct 23
DEFA14A
Additional proxy soliciting materials
10 Oct 23
DFAN14A
Additional proxy materials by non-management
10 Oct 23
Other
EFFECT
Notice of effectiveness
25 Jan 24
EFFECT
Notice of effectiveness
25 Jan 24
EFFECT
Notice of effectiveness
25 Jan 24
CT ORDER
Confidential treatment order
22 Apr 21
CT ORDER
Confidential treatment order
26 Apr 19
CT ORDER
Confidential treatment order
21 Aug 18
CT ORDER
Confidential treatment order
16 May 16
EFFECT
Notice of effectiveness
18 Nov 15
UPLOAD
Letter from SEC
16 Nov 15
CORRESP
Correspondence with SEC
16 Nov 15
Ownership
SC 13G
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Avoro Capital Advisors LLC
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
MORGAN STANLEY
9 Feb 24
SC 13G
MORGAN STANLEY
9 Feb 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
SC 13G
BlackRock Inc.
31 Jan 24
4
JOSEPH LEWIS
25 Jan 24